NCT02354053View on ClinicalTrials.gov

Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations

PHASE4CompletedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

July 3, 2018

Study Completion Date

July 2, 2019

Conditions

HIV Infections

Interventions

DRUG

Switch to Triumeq

BEHAVIORAL

Adherence support + current ART

Trial Locations (1)

H4A 3J1

Chronic Viral Illness Service, Montreal

Sponsors

Collaborators (1)

ViiV Healthcare

All Listed Sponsors

collaborator

ViiV Healthcare

INDUSTRY

collaborator

CIHR Canadian HIV Trials Network

NETWORK

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT02354053 - Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations | Biotech Hunter | Biotech Hunter